Melanoma cells interfere with the interaction of dendritic cells with NK/LAK cells
Annalisa Capobianco
Department of Oncology, Cancer Immunotherapy and Gene Therapy Program, Clinical Immunology Unit, H San Raffaele Scientific Institute & Vita-Salute San Raffaele University, Milano, Italy
Search for more papers by this authorPatrizia Rovere-Querini
Department of Oncology, Cancer Immunotherapy and Gene Therapy Program, Clinical Immunology Unit, H San Raffaele Scientific Institute & Vita-Salute San Raffaele University, Milano, Italy
Search for more papers by this authorClaudio Rugarli
Department of Oncology, Cancer Immunotherapy and Gene Therapy Program, Clinical Immunology Unit, H San Raffaele Scientific Institute & Vita-Salute San Raffaele University, Milano, Italy
Search for more papers by this authorCorresponding Author
Angelo A. Manfredi
Department of Oncology, Cancer Immunotherapy and Gene Therapy Program, Clinical Immunology Unit, H San Raffaele Scientific Institute & Vita-Salute San Raffaele University, Milano, Italy
Fax: +39-02-2643-4786
H San Raffaele DIBIT 3A1, via Olgettina 58, Milano 20132, ItalySearch for more papers by this authorAnnalisa Capobianco
Department of Oncology, Cancer Immunotherapy and Gene Therapy Program, Clinical Immunology Unit, H San Raffaele Scientific Institute & Vita-Salute San Raffaele University, Milano, Italy
Search for more papers by this authorPatrizia Rovere-Querini
Department of Oncology, Cancer Immunotherapy and Gene Therapy Program, Clinical Immunology Unit, H San Raffaele Scientific Institute & Vita-Salute San Raffaele University, Milano, Italy
Search for more papers by this authorClaudio Rugarli
Department of Oncology, Cancer Immunotherapy and Gene Therapy Program, Clinical Immunology Unit, H San Raffaele Scientific Institute & Vita-Salute San Raffaele University, Milano, Italy
Search for more papers by this authorCorresponding Author
Angelo A. Manfredi
Department of Oncology, Cancer Immunotherapy and Gene Therapy Program, Clinical Immunology Unit, H San Raffaele Scientific Institute & Vita-Salute San Raffaele University, Milano, Italy
Fax: +39-02-2643-4786
H San Raffaele DIBIT 3A1, via Olgettina 58, Milano 20132, ItalySearch for more papers by this authorAbstract
Dendritic cells (DCs) and natural killer (NK) cells are key players at the interface between innate resistance and acquired immunity. NK cells can induce DC maturation, a differentiation process whereby DCs respond to a environmental stimulus and acquire the ability of eliciting adaptive immunity. Conversely, maturing DCs promote NK functions in vivo and in vitro. This interplay has important consequences on the immune response to pathogens and possibly to neoplastic cells. Here, we show that B16 melanoma cells actively modulate the interaction between DCs derived from bone marrow precursors and NK/LAK cells propagated from the spleen of C57BL/6 mice. DCs increased in a dose-dependent manner the ability of NK/LAK cells to kill melanoma cells and to produce cytokines. This activatory cross-talk entailed the production of IL-18 by DCs and of IFN-γ by NK/LAK cells. Melanoma cells were not a passive target of NK activity; they regulated the outcome of the interaction between DCs and NK/LAK cells, inhibiting the in vitro production of cytokines as effectively as the genetic deletion of IL-18 or IFN-γ. Interference with the NK/DC interaction possibly represents a mechanism used by growing tumors to evade the immune response. © 2006 Wiley-Liss, Inc.
References
- 1 Trinchieri G. Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin Immunol 1995; 7: 83–8.
- 2 Lanier LL. Activating and inhibitory NK cell receptors. Adv Exp Med Biol 1998; 452: 13–18.
- 3 Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999; 17: 875–904.
- 4 Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002; 2: 957–64.
- 5 Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA. NK cell and DC interactions. Trends Immunol 2004; 25: 47–52.
- 6 Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural killer cells and dendritic cells: “l'union fait la force”. Blood 2005; 106: 2252–8.
- 7 Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med 2002; 195: F9–F14.
- 8 Mocikat R, Braumuller H, Gumy A, Egeter O, Ziegler H, Reusch U, Bubeck A, Louis J, Mailhammer R, Riethmuller G, Koszinowski U, Rocken M. Natural killer cells activated by MHC class I (low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003; 19: 561–9.
- 9 Vitale M, Della Chiesa M, Carlomagno S, Pende D, Arico M, Moretta L, Moretta A. NK-dependent DC maturation is mediated by TNFα and IFNγ released upon engagement of the NKp30 triggering receptor. Blood 2005; 106: 566–71.
- 10 Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 2005; 202: 203–7.
- 11 Semino C, Angelini G, Poggi A, Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 2005; 106: 609–16.
- 12 Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5: 405–11.
- 13 Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J, Davoust J, Palucka KA, Banchereau J. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999; 190: 1417–26.
- 14 Movassagh M, Spatz A, Davoust J, Lebecque S, Romero P, Pittet M, Rimoldi D, Lienard D, Gugerli O, Ferradini L, Robert C, Avril MF, et al. Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res 2004; 64: 2192–8.
- 15 Furumoto K, Soares L, Engleman EG, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 2004; 113: 774–83.
- 16 Crittenden MR, Thanarajasingam U, Vile RG, Gough MJ. Intratumoral immunotherapy: using the tumour against itself. Immunology 2005; 114: 11–22.
- 17 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539–45.
- 18 Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461–6.
- 19 Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211–17.
- 20 Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G, Lackner A, Carmeliet P, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004; 64: 5535–8.
- 21 Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, Steinman RM. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003; 198: 235–47.
- 22
Nikitina EY,
Gabrilovich DI.
Combination of γ-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer.
Int J Cancer
2001;
94:
825–33.
10.1002/1097-0215(20011215)94:6<825::AID-IJC1545>3.0.CO;2-5 CAS PubMed Web of Science® Google Scholar
- 23 Candido KA, Shimizu K, McLaughlin JC, Kunkel R, Fuller JA, Redman BG, Thomas EK, Nickoloff BJ, Mule JJ. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res 2001; 61: 228–36.
- 24 Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 2001; 61: 7530–5.
- 25 Schmidt T, Ziske C, Marten A, Endres S, Tiemann K, Schmitz V, Gorschluter M, Schneider C, Sauerbruch T, Schmidt-Wolf IG. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res 2003; 63: 8962–7.
- 26 Teitz-Tennenbaum S, Li Q, Rynkiewicz S, Ito F, Davis MA, McGinn CJ, Chang AE. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 2003; 63: 8466–75.
- 27 Murakami T, Tokunaga N, Waku T, Gomi S, Kagawa S, Tanaka N, Fujiwara T. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene. Clin Cancer Res 2004; 10: 3871–80.
- 28 Hatfield P, Merrick A, Harrington K, Vile R, Bateman A, Selby P, Melcher A. Radiation-induced cell death and dendritic cells: potential for cancer immunotherapy? Clin Oncol (R Coll Radiol) 2005; 17: 1–11.
- 29 Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P, Rugarli C, Manfredi AA. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998; 161: 4467–71.
- 30 Rovere P, Sabbadini MG, Vallinoto C, Fascio U, Zimmermann VS, Bondanza A, Ricciardi-Castagnoli P, Manfredi AA. Delayed clearance of apoptotic lymphoma cells allows cross-presentation of intracellular antigens by mature dendritic cells. J Leukoc Biol 1999; 66: 345–9.
- 31 Valteau-Couanet D, Leboulaire C, Maincent K, Tournier M, Hartmann O, Benard J, Beaujean F, Boccaccio C, Zitvogel L, Angevin E. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood 2002; 100: 2554–61.
- 32 Ahmad M, Rees RC, McArdle SE, Li G, Mian S, Entwisle C, Loudon P, Ali SA. Regulation of CTL responses to MHC-restricted class I peptide of the gp70 tumour antigen by splenic parenchymal CD4+ T cells in mice failing immunotherapy with DISC-mGM-CSF. Int J Cancer 2005; 115: 951–9.
- 33
Bondanza A,
Rovere P,
Borri A,
Caremoli ER,
Guidetti A,
Citterio G,
Consogno G,
Zimmermann VS,
Rugarli C,
Manfredi AA.
Cytokine secretion associated with the clearance of apoptotic bodies in renal cell carcinoma patients.
Int J Cancer
2001;
91:
713–17.
10.1002/1097-0215(200002)9999:9999<::AID-IJC1096>3.0.CO;2-G CAS PubMed Web of Science® Google Scholar
- 34 Zimmermann VS, Bondanza A, Rovere-Querini P, Colombo B, Sacchi A, Fascio U, Corti A, Manfredi AA. Characterisation of functional biotinylated TNF-α targeted to the membrane of apoptotic melanoma cells. J Immunol Methods 2003; 276(1/2): 79–87.
- 35 Bellone M, Iezzi G, Rovere P, Galati G, Ronchetti A, Protti MP, Davoust J, Rugarli C, Manfredi AA. Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol 1997; 159: 5391–9.
- 36 Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-γ for T(H)1 priming. Nat Immunol 2004; 5: 1260–5.
- 37 Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004; 4: 941–52.
- 38 Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, Kroemer G, Martin F, Chauffert B, Zitvogel L. Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005; 202: 919–29.
- 39 Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB. Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther 2005; 5: 1303–15.
- 40 Kamiryo Y, Yajima T, Saito K, Nishimura H, Fushimi T, Ohshima Y, Tsukamoto Y, Naito S, Yoshikai Y. Soluble branched (1,4)-β-D-glucans from Acetobacter species enhance antitumor activities against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int J Cancer 2005; 115: 769–76.
- 41 Massa C, Melani C, Colombo MP. Chaperon and adjuvant activity of hsp70: different natural killer requirement for cross-priming of chaperoned and bystander antigens. Cancer Res 2005; 65: 7942–9.
- 42 Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005; 65: 11136–45.
- 43 Tanaka K, Ito A, Kobayashi T, Kawamura T, Shimada S, Matsumoto K, Saida T, Honda H. Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles. Int J Cancer 2005; 116: 624–33.
- 44 Seliger B, Ritz U, Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 2006; 118: 129–38.
- 45 Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJ. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 2003; 24: 603–9.
- 46 Vicari AP, Treilleux I, Lebecque S. Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin Cancer Biol 2004; 14: 161–9.
- 47 Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004; 23: 255–9.
- 48 Marcenaro E, Della Chiesa M, Bellora F, Parolini S, Millo R, Moretta L, Moretta A. IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol 2005; 174: 3992–8.
- 49 Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195: 327–33.
- 50 Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002; 195: 335–41.
- 51 Ishikawa E, Motohashi S, Ishikawa A, Ito T, Uchida T, Kaneko T, Tanaka Y, Horiguchi S, Okamoto Y, Fujisawa T, Tsuboi K, Taniguchi Met al. Dendritic cell maturation by CD11c- T cells and Vα 24+ natural killer T-cell activation by α-galactosylceramide. Int J Cancer 2005; 117: 265–73.
- 52 Minami K, Yanagawa Y, Iwabuchi K, Shinohara N, Harabayashi T, Nonomura K, Onoe K. Negative feedback regulation of T helper type 1 (Th1)/Th2 cytokine balance via dendritic cell and natural killer T cell interactions. Blood 2005; 106: 1685–93.
- 53 Moretta A, Marcenaro E, Sivori S, Della Chiesa M, Vitale M, Moretta L. Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol 2005; 26: 668–75.